Working with TipRanks
Follow Us
Stock Ideas
Daily Updates
Calendars
Education
About Us
Working with TipRanks
Follow Us
Alnylam Pharmaceuticals (ALNY)
NASDAQ:ALNY
Alnylam Pharma (ALNY) Stock Price & Analysis
920 Followers
ALNY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$122.57 - $242.97
Previous Close$192.3
Volume263.20K
Average Volume (3M)741.71K
Market Cap
$23.95B
Enterprise Value$23.20B
Total Cash (Recent Filing)$2.07B
Total Debt (Recent Filing)$1.32B
Price to Earnings (P/E)-22.1
Beta0.78
Next Earnings
Aug 01, 2023EPS Estimate
-$1.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.70
Shares Outstanding124,525,737
10 Day Avg. Volume511,538
30 Day Avg. Volume741,710
Standard Deviation0.13
R-Squared0.04
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)-87.19
Price to Sales (P/S)75.00
Price to Cash Flow (P/CF)-34.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue16.48
Enterprise Value/Gross Profit13.10
Enterprise Value/Ebitda-38.86
Forecast
1Y Price Target
$255.21Price Target Upside32.26% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
Alnylam Pharma News
Pre-EarningsIs ALNY a Buy, Before Earnings?
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Product Insights
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ALNY FAQ
What was Alnylam Pharmaceuticals’s price range in the past 12 months?
Alnylam Pharmaceuticals lowest stock price was $122.57 and its highest was $242.97 in the past 12 months.
What is Alnylam Pharmaceuticals’s market cap?
Currently, no data Available
When is Alnylam Pharmaceuticals’s upcoming earnings report date?
Alnylam Pharmaceuticals’s upcoming earnings report date is Aug 01, 2023 which is in 55 days.
How were Alnylam Pharmaceuticals’s earnings last quarter?
Alnylam Pharmaceuticals released its earnings results on May 04, 2023. The company reported -$1.4 earnings per share for the quarter, beating the consensus estimate of -$1.67 by $0.27.
Is Alnylam Pharmaceuticals overvalued?
According to Wall Street analysts Alnylam Pharmaceuticals’s price is currently Undervalued.
Does Alnylam Pharmaceuticals pay dividends?
Alnylam Pharmaceuticals does not currently pay dividends.
What is Alnylam Pharmaceuticals’s EPS estimate?
Alnylam Pharmaceuticals’s EPS estimate is -$1.51.
How many shares outstanding does Alnylam Pharmaceuticals have?
Alnylam Pharmaceuticals has 124,525,734 shares outstanding.
What happened to Alnylam Pharmaceuticals’s price movement after its last earnings report?
Alnylam Pharmaceuticals reported an EPS of -$1.4 in its last earnings report, beating expectations of -$1.67. Following the earnings report the stock price went up 2.952%.
Which hedge fund is a major shareholder of Alnylam Pharmaceuticals?
Among the largest hedge funds holding Alnylam Pharmaceuticals’s share is Dodge & Cox. It holds Alnylam Pharmaceuticals’s shares valued at 780M.
---
Alnylam Pharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$255.21 (32.26% Upside)
$255.21 (32.26% Upside)
Blogger Sentiment
Bullish
ALNY Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 3.8%
Last 30 Days ▲ 3.8%
News Sentiment
Neutral
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
46.21%
12-Months-Change
Fundamentals
Return on Equity
-1500.66%
Trailing 12-Months
Asset Growth
-1.21%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
---
Top 5 ETFs holding ALNY
Vanguard Growth ETF
$210.58M
Vanguard Health Care ETF
$80.59M
iShares Russell 1000 Growth ETF
$76.77M
Vanguard Large-Cap ETF
$26.99M
Capital Group Growth ETF
$26.80M
Up to five ETFs with an Outperform Smart Score that hold ALNY. The ETFs are listed according to market value of ALNY within the ETF
---
---